{
  "pmcid": "11004700",
  "sha256": "c335a82e8a94b537882a1a7e0bd70458464bdd08da1f3cad378acce31da819e5",
  "timestamp_utc": "2025-11-09T23:11:27.787194+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 8.849965277777777,
    "reading_ease": 48.5003587962963,
    "word_count": 256
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Polidocanol Foam Sclerotherapy vs. Conventional Surgery for Varicose Veins"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Sample size calculation aimed to detect a 1.5-point difference in VCSS with 80% power and 95% confidence."
      },
      "Participants": {
        "score": 2,
        "evidence": "205 patients were recruited from two public health institutions in São Paulo, Brazil"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were non-randomly assigned to PFS (57 patients, 90 legs) or CS (148 patients, 236 legs)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluated the effectiveness of polidocanol foam sclerotherapy (PFS) compared to conventional surgery (CS) for treating lower limb varicose veins, focusing on Patient-Reported Outcome Measures (PROMs)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in Venous Clinical Severity Score (VCSS) and VEINES-QoL/Sym scores, measured preoperatively and 30 days post-treatment."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Participants were non-randomly assigned to PFS (57 patients, 90 legs) or CS (148 patients, 236 legs)."
      },
      "Blinding": {
        "score": 0,
        "evidence": "The study was not randomised, and no blinding was used."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "205 patients were recruited from two public health institutions in São Paulo, Brazil, between October 2021 and October 2022."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Participants were non-randomly assigned to PFS (57 patients, 90 legs) or CS (148 patients, 236 legs)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "CS demonstrated greater improvements in VCSS (mean difference = 4.02, 95% CI 3.1 to 5.0; p < 0.001), VEINES-QoL (mean difference = 8, 95% CI 6.5 to 9.5; p < 0.001), and VEINES-Sym (mean difference = 11.66, 95% CI 9.8 to 13.5; p < 0.001) compared to PFS."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported in either group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not disclosed."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}